Drugs.com - New Drug Approvals

FDA Approves Expanded Use of Soliris (eculizumab) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children

New York, March 10, 2025 – The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six...

Mar 31, 2025 - 06:31
 0
FDA Approves Expanded Use of Soliris (eculizumab) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
New York, March 10, 2025 – The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients aged six...
Read More

Tags:

Previous Article

Runaway Risk Tool enables site-specific safety measures

Next Article

Indian RBI’s monetary easing to be limited to 75 bps in FY26: Ind-Ra

Related Posts

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

scPharmaceuticals Announces FDA Approval of Supplementa...

Mar 9, 2025  0

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025  0

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar ...

Feb 9, 2025  0